GAMMA Investing LLC Purchases 408 Shares of Hologic, Inc. (NASDAQ:HOLX)

GAMMA Investing LLC grew its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 19.6% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,493 shares of the medical equipment provider’s stock after purchasing an additional 408 shares during the quarter. GAMMA Investing LLC’s holdings in Hologic were worth $194,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of HOLX. McGlone Suttner Wealth Management Inc. bought a new position in Hologic during the fourth quarter valued at approximately $27,000. Massmutual Trust Co. FSB ADV boosted its stake in shares of Hologic by 69.4% in the 4th quarter. Massmutual Trust Co. FSB ADV now owns 554 shares of the medical equipment provider’s stock valued at $40,000 after purchasing an additional 227 shares in the last quarter. Allworth Financial LP grew its holdings in shares of Hologic by 39.3% during the 4th quarter. Allworth Financial LP now owns 634 shares of the medical equipment provider’s stock valued at $45,000 after purchasing an additional 179 shares during the last quarter. Livforsakringsbolaget Skandia Omsesidigt raised its position in Hologic by 145.3% in the 4th quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 790 shares of the medical equipment provider’s stock worth $56,000 after purchasing an additional 468 shares during the period. Finally, BKM Wealth Management LLC bought a new stake in Hologic in the fourth quarter worth $86,000. 94.73% of the stock is owned by hedge funds and other institutional investors.

Hologic Price Performance

Shares of NASDAQ HOLX opened at $72.21 on Friday. Hologic, Inc. has a 1 year low of $64.02 and a 1 year high of $82.45. The stock has a market capitalization of $16.85 billion, a P/E ratio of 36.84, a P/E/G ratio of 2.38 and a beta of 1.00. The company’s 50-day moving average is $74.67 and its 200 day moving average is $74.11. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.97 and a quick ratio of 3.29.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.03 earnings per share for the quarter, beating the consensus estimate of $0.98 by $0.05. Hologic had a return on equity of 18.91% and a net margin of 11.78%. The business had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1 billion. During the same period in the previous year, the firm posted $1.06 EPS. The business’s revenue was down .8% on a year-over-year basis. On average, sell-side analysts expect that Hologic, Inc. will post 4.08 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on HOLX shares. Citigroup upgraded Hologic from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $80.00 to $95.00 in a report on Wednesday, April 3rd. Argus boosted their price objective on Hologic from $89.00 to $95.00 and gave the company a “buy” rating in a research report on Thursday, May 9th. Needham & Company LLC restated a “buy” rating and issued a $90.00 target price on shares of Hologic in a report on Friday, May 3rd. Evercore ISI upped their price target on shares of Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a report on Thursday, April 4th. Finally, JPMorgan Chase & Co. raised their price target on shares of Hologic from $85.00 to $91.00 and gave the stock an “overweight” rating in a report on Friday, May 3rd. Five research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $85.60.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.